Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program
In 522 patients, average weight loss was approximately 32 pounds at balloon passage and 31
In 497 patients, average weight loss was
In the first study, 522 patients treated with the Allurion Program across nine international obesity centers reduced their weight, on average, by 14.4kg (32lbs) or
In the second study, 497 patients treated with the Allurion Program at a single center between January 2020 and January 2024 reduced their weight, on average, by
“Two of the key tenets of metabolically healthy weight loss are losing weight and keeping it off,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “We are pleased to see an increasing number of publications that demonstrate that the Allurion Program delivers fast weight loss results that can be maintained in the long-term, through an emphasis on behavior change delivered through our AI-powered Virtual Care Suite.”
About Allurion
Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, Procedureless™ gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.
Allurion is a trademark of Allurion Technologies, Inc. in
Forward-Looking Statements
This press release contains forward-looking statements that reflect Allurion’s beliefs and assumptions based on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terms, although not all forward-looking statements contain these words. Although Allurion believes it has a reasonable basis for each forward-looking statement contained in this release, these statements involve risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
Forward-looking statements in this press release include, but are not limited to, statements regarding: establishing a new standard for weight loss; pioneering in metabolically healthy weight loss; the ability of the Allurion program to drive weight loss and weight loss maintenance; the uniqueness of Allurion’s product and service offerings, including the Allurion Program and Virtual Care Suite; and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to management.
Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Program, including the Allurion Balloon; the timing of, and results from, Allurion’s clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Balloon; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to maintain its listing on the New York Stock Exchange; a changing regulatory landscape in the highly competitive industry in which Allurion competes; the impact of the imposition of current and potential tariffs and trade negotiations, and those factors discussed under the heading “Risk Factors” in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 27, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.
____________________ |
1 Caballero, A., Giardiello, C., Schiano Di Cola, R. et al. Weight Loss Maintenance 1 Year after the Swallowable Gastric Balloon: Results from an International Multicenter Study. Obes Surg (2025). https://doi.org/10.1007/s11695-025-08074-2 |
2 Palermo, M. and Davrieux, F. Swallowable Gastric Balloon: As a Noninvasive Option for Weight Loss. J Laparoendo Adv Surg Tech (2025). doi: 10.1177/10926429251359390. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250722775093/en/
Media Contact
Allurion Press Office
Woodrow Communications
allurion@woodrowcommunications.com
Investor Contact
investors@allurion.com
Source: Allurion Technologies, Inc.
